• Patient dosing underway for Registrational Phase 3 clinical trial in Indonesia
• RECCE® 327 Topical Gel highly effective against antibiotic-resistant pathogens in animal studies
• R327 recognized in WHO's 2025 Global Antibacterial Pipeline Report

Recce Pharmaceuticals Ltd released its Q1 FY2026 results and operational highlights. Key points include:- Patient dosing is underway for the Registrational Phase 3 clinical trial in Indonesia for Diabetic Foot Infections (DFI), with five clinical trial sites activated and a target enrolment of up to 310 patients.- The company announced positive in-vivo data for RECCE® 327 Topical Gel (R327G), showing it was highly effective against Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infected burn wounds, achieving statistically significant reductions in bacterial load and improved wound healing.- R327 was recognized in the World Health Organization's 2025 report on antibacterial agents in clinical and preclinical development, listed as the only synthetic polymer antibiotic in clinical development.- The company presented research at the 2025 United States Military Health System Research Symposium, demonstrating R327's activity against multiple high-priority bioterrorism pathogens.- The company ended the quarter with a cash balance of A$3.17 million and expects a near-term cash inflow from an R&D rebate, positioning it for multiple near-term value catalysts including the interim analysis of its Phase 3 trial in Q1 2026.

The company remains well placed to deliver clinical and commercial outcomes in the coming months with near-term inflows, advancing clinical programs, and expanding global recognition of its lead candidate R327.